

R James White

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7850755/publications.pdf>

Version: 2024-02-01

58
papers

3,561
citations

331259

21
h-index

168136

53
g-index

58
all docs

58
docs citations

58
times ranked

2851
citing authors

#	ARTICLE	IF	CITATIONS
1	Tadalafil Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 2894-2903.	1.6	956
2	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 834-844.	13.9	906
3	Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 624-633.	1.6	291
4	Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 137-149.	0.3	180
5	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	5.2	122
6	Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 293, L583-L590.	1.3	116
7	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89
8	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	2.5	88
9	Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. <i>Liver Transplantation</i> , 2009, 15, 30-36.	1.3	86
10	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 573-584.	5.2	85
11	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 894-901.	5.2	59
12	Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 193-201.	0.3	50
13	Thrombosis, platelets, microparticles and PAH: more than a clot. <i>Drug Discovery Today</i> , 2014, 19, 1230-1235.	3.2	42
14	Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease. <i>PLoS ONE</i> , 2015, 10, e0127443.	1.1	42
15	The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 331-335.	1.0	34
16	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 834-842.	0.5	31
17	Pharmacokinetics of Oral Treprostinil Sustained Release Tablets During Chronic Administration to Patients with Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 474-481.	0.8	30
18	Subcutaneous Treprostinil is Well Tolerated with Infrequent Site Changes and Analgesics. <i>Pulmonary Circulation</i> , 2013, 3, 611-621.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. <i>Pulmonary Circulation</i> , 2017, 7, 167-174.	0.8	29
20	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 751-760.	2.5	27
21	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2640-2645.	1.9	26
22	Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L706-L714.	1.3	20
23	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 35-46.	5.2	17
24	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , 2019, 20, 208.	1.4	16
25	Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2020, 72, 1759-1770.	2.9	14
26	Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats. <i>Experimental Lung Research</i> , 2018, 44, 51-61.	0.5	13
27	Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. <i>ERJ Open Research</i> , 2021, 7, 00554-2020.	1.1	13
28	Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1434-1436.	2.5	12
29	Tissue Factor Is Induced in a Rodent Model of Severe Pulmonary Hypertension Characterized by Neointimal Lesions Typical of Human Disease. <i>Chest</i> , 2005, 128, 612S-613S.	0.4	11
30	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2583-2593.	0.9	11
31	Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension. <i>Hypertension</i> , 2022, 79, 79-92.	1.3	11
32	Heart Rate Expenditure Correlates with Right Ventricular Function. <i>Annals of the American Thoracic Society</i> , 2020, 17, 372-375.	1.5	10
33	A Pharmacokinetic and Tolerability Comparison in Subjects Transitioning From Twice Daily to Three Times Daily Dosing of Oral Treprostinil. <i>Chest</i> , 2014, 146, 865A.	0.4	9
34	Estrogen: Friend or Foe in Pulmonary Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1084-1086.	2.5	9
35	Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	0.8	9
36	Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2022, 193, 106744.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Heart rate monitoring improves clinical assessment during 6-min walk. <i>Pulmonary Circulation</i> , 2020, 10, 204589402097257.	0.8	7
38	Liver Backscatter and the Hepatic Vasculature's Autocorrelation Function. <i>Acoustics</i> , 2020, 2, 3-12.	0.8	7
39	New Therapeutic Approaches in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 2390-2392.	1.6	5
40	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-10.	0.8	5
41	Traversing and labeling interconnected vascular tree structures from 3D medical images. , 2014, , .		4
42	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	0.8	4
43	Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza. <i>Thrombosis Research</i> , 2021, 205, 40-43.	0.8	4
44	Pulmonary arterial hypertension: building a better mouse trap for 2010. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 351-359.	0.5	3
45	Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed. <i>Drug Discovery Today</i> , 2014, 19, 1226-1229.	3.2	3
46	Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. <i>Respiratory Medicine</i> , 2021, 188, 106596.	1.3	3
47	Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH. <i>Advances in Pulmonary Hypertension</i> , 2009, 8, 32-36.	0.1	3
48	Comparison of chest- and wrist-based actigraphy in pulmonary arterial hypertension. <i>European Heart Journal Digital Health</i> , 2022, 3, 90-97.	0.7	3
49	Combination therapy improves vascular volume in female rats with pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L445-L455.	1.3	2
50	Evaluation of Clinical Recovery After Surgical Treatment for Hand Ischemia From Vasospastic and Occlusive Disease Using PROMIS. <i>Hand</i> , 2023, 18, 15-21.	0.7	2
51	8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain. <i>Pain Medicine</i> , 2017, 18, 2515-2517.	0.9	1
52	Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	0.8	1
53	Resting heart rate as a surrogate for improvement in intermediate risk pulmonary embolus patients?. <i>Respiratory Medicine</i> , 2021, 187, 106578.	1.3	1
54	An Untapped Resource: Characteristics of Thrombus Recovered from Intermediate or High Risk Pulmonary Embolus Patients. <i>Cardiovascular Pathology</i> , 2021, 57, 107392.	0.7	1

#	ARTICLE	IF	CITATIONS
55	Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension. Respiratory Medicine Case Reports, 2022, 37, 101646.	0.2	1
56	P0229APPLICATION OF A RISK MITIGATION STRATEGY TO PREVENT EXCESS CARDIOVASCULAR RISK IN PULMONARY HYPERTENSION: LARIAT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
57	Selexipag Use in Clinical Practice. Chest, 2020, 157, 761-763.	0.4	0
58	Guest Editor's Memo. Advances in Pulmonary Hypertension, 2012, 11, 2-48.	0.1	0